Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza B virus hemagglutinin (HA) from the Victoria lineage is a trimeric viral envelope glycoprotein responsible for binding sialic acid receptors on host cells to facilitate attachment and mediating membrane fusion via low-pH-induced conformational changes in its HA1 (receptor-binding and vestigial esterase subdomains) and HA2 (fusion peptide and coiled-coil) subunits. It features conserved structural elements like disulfide bridges, glycosylation sites (e.g., HA1-145 on 150 loop), and ionizable residues for pH sensitivity, with major antigenic sites (120 loop, 150 loop, 160 loop, 190 helix) forming a continuous surface prone to substitutions for immune evasion. Crystal structures (e.g., B/Hong Kong/8/73 at 2.8 Å) reveal differences from influenza A HA, such as fusion peptide positioning and unique disulfides, while Victoria-lineage viruses show key substitutions near the RBS (e.g., 150KN, 203TK) defining antigenic separation from Yamagata lineage.
Neutralizing antibodies bind receptor-binding site (RBS) or antigenic sites to block attachment or fusion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza B virus hemagglutinin (Victoria lineage) (HA).